Chemistry:25iP-NBOMe

From HandWiki

25iP-NBOMe, also known as 2C-iP-NBOMe or NBOMe-2C-iP, is a derivative of the phenethylamine hallucinogen 2C-iP, which has been encountered as a novel designer drug.[1][2]

Toxicity and harm potential

Neurotoxic and cardiotoxic actions

Emergency treatment

Interactions

Pharmacology

The interactions of 25iP-NBOMe with the μ-opioid receptor have been described.[3]

History

25iP-NBOMe was first described in the scientific literature by at least 2014, when it was encountered as a novel designer drug.[1]

Society and culture

Canada

25iP-NBOMe is a controlled substance in Canada under phenethylamine blanket-ban language.[4]

United Kingdom

This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.[5]


See also

Notes

References

  1. 1.0 1.1 "New phenethylamines in Europe". Drug Test Anal 6 (7–8): 808–18. 2014. doi:10.1002/dta.1570. PMID 24574327. 
  2. "Prevalence of use and acute toxicity associated with the use of NBOMe drugs". Clin Toxicol (Phila) 53 (2): 85–92. February 2015. doi:10.3109/15563650.2015.1004179. PMID 25658166. 
  3. "Off-target activity of NBOMes and NBOMe analogs at the µ opioid receptor". Arch Toxicol 97 (5): 1367–1384. May 2023. doi:10.1007/s00204-023-03465-9. PMID 36853332. Bibcode2023ArTox..97.1367D. 
  4. "Controlled Drugs and Substances Act". https://laws-lois.justice.gc.ca/eng/acts/c-38.8/FullText.html. 
  5. "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014" (in en). http://www.legislation.gov.uk/uksi/2014/1106/made.